|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Salix Pharmaceuticals |
|---|---|
| Information provided by: | Salix Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01008423 |
Purpose
The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam administered as 2mg/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in subjects who present with a diagnosis of active, mild to moderate, ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS). During the study, eligible subjects will be allowed to maintain previously established oral 5-ASA treatment at doses up to 4.8g/day.
| Condition | Intervention | Phase |
|---|---|---|
|
Proctitis Proctosigmoiditis |
Drug: Budesonide Drug: Placebo |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis |
| Estimated Enrollment: | 430 |
| Study Start Date: | November 2009 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Budesonide
Budesonide rectal foam
|
Drug: Budesonide
2mg/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks
|
|
Placebo Comparator: Placebo
Placebo foam
|
Drug: Placebo
Placebo foam/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks
|
This is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of budesonide foam in subjects with active mild to moderate proctitis or proctosigmoiditis. Approximately 430 subjects will be enrolled into the study and receive either placebo foam or budesonide foam twice a day for 2 weeks followed by once a day for 4 weeks. Participation in the study will last approximately 11 weeks, depending on the timing of study visits.
During the study, eligible subjects will be allowed to maintain previously established oral 5-ASA treatment at doses up to 4.8g/day. Periodic safety monitoring, including physical examinations, vitals, laboratory testing, and recording of AEs and concomitant medications, will be performed during the study
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Barbara Orban | 919-862-1000 | barbara.orban@salix.com |
| Contact: Melanie Klotz | 919-862-1000 | melanie.klotz@salix.com |
Show 66 Study Locations
More Information
| Responsible Party: | Michelle Widmann, Assoicate Director - Clinical Operations, Salix Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT01008423 History of Changes |
| Other Study ID Numbers: | BUCF3002 |
| Study First Received: | November 4, 2009 |
| Last Updated: | July 17, 2011 |
| Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
|
Proctitis Proctosigmoiditis Ulcerative Salix Budesonide foam Budesonide Rectal Gastrointestinal Colitis UC UP UPS Additional relevant MeSH terms: Proctocolitis Ulcer |
Colitis, Ulcerative Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Rectal Diseases Intestinal Diseases Colonic Diseases Sigmoid Diseases Pathologic Processes Inflammatory Bowel Diseases Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions |
|
Proctitis Proctocolitis Ulcer Colitis, Ulcerative Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Rectal Diseases Intestinal Diseases Colitis Colonic Diseases Sigmoid Diseases Pathologic Processes Inflammatory Bowel Diseases |
Anti-Inflammatory Agents Budesonide Bronchodilator Agents Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Asthmatic Agents Peripheral Nervous System Agents Respiratory System Agents Physiological Effects of Drugs Therapeutic Uses Pharmacologic Actions Autonomic Agents Glucocorticoids Hormones |